Kilitch Drugs India Ltd
- P/E
- 25x
- 52-week range
- 117.25 – 232.5
- ROE
- 11%
- ROCE
- 13%
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Pharmaceuticals
- Listed on
- NSE, BSE
About
Kilitch Drugs (India) Limited is an India-based pharmaceutical manufacturing company. The Company is mainly engaged in the development and operations of the pharmaceutical business. Its services range from manufacturing to marketing a host of formulations in all dosage forms. The Company offers products in the categories of Parenteral and Nasal Products, Oral, Effervescent, Nutritional Products, Medical Devices, and Cosmetics and Herbal Products. It offers products that help in gastroenterology, anti-inflammatory, anti-malaria, diagnostics, uterine stimulants, veterinary and many more areas in the form of ampoules & vials. Its range of oral formulations includes tablets, capsules, dry syrups and oral powders. It provides a range of cosmetics ranging from oil, lotion, liquid to cream and paste in the skin care, personal care and hair care categories. It offers a medical device, namely, the C-Seal. ROIPAR, ROIVIT, PH-7, C-SEAL, SRO-KIT, 9-VIT, HPURE are their product offerings.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Pharmaceuticals: 221 companies →Kilitch Drugs India Ltd against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)25 against a typical 34.3: cheaper than most peers (1st = cheapest).80th of 220
- Sales growth+4% against a typical +15.6% from a year earlier.139th of 197
- Profit growth−13.7% against a typical +18.9% from a year earlier.110th of 160
- Share price, 3 months+18.2% against a typical −0.5%.38th of 200
Latest announcements
Exchange filings and their impact on the company.
- 22 Oct 2026Outcome of Board MeetingHigh impactPositiveKilitch to sell its loss-making Ethiopia unit for ~Rs 113 cr, losing 20% sales but booking a large one-time profit.
Kilitch Drugs board on 22 Oct 2026 approved sale of its entire stake in material subsidiary Kilitch Estro Biotech PLC, Ethiopia, to HarmeeCare Pharmaceuticals for USD 14 million total, with USD 12.855 million (~Rs 113 crore) due to Kilitch. KEB had Rs 47.57 crore sales (20.2% of consolidated sales) and Rs -8.43 crore net worth in FY26. Before the sale, Kilitch will convert up to Rs 57 crore of loans to KEB into 1,66,472 shares at Rs 3,414 each, with completion targeted by 31 Jan 2027 subject to shareholder approval. The board also appointed two new independent directors.
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 13 Aug 2026 | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2026 |
| 15 May 2026 | Financial Results | To consider and approve the financial results for the period ended March 31, 2026 |
| 11 Feb 2026 | Other business matters | to consider increase in authorised capital, to convene EGM, to finalise record date |
| 13 Nov 2025 | Financial Results | To consider and approve the financial results for the period ended September 30, 2025 |
| 13 Aug 2025 | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2025 |
| 2 Jul 2025 | Fund Raising | To consider Fund Raising |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 41 | 32 | 45 | 33 | 47 | 56 | 61 | 43 | 49 | 54 | 90 | 45 |
| Expenses | 33 | 30 | 38 | 32 | 41 | 47 | 47 | 40 | 44 | 48 | 67 | 42 |
| Operating Profit | 9 | 2 | 7 | 2 | 6 | 9 | 15 | 3 | 5 | 6 | 22 | 3 |
| OPM % | 20.9% | 7.2% | 15.8% | 5% | 12.9% | 15.5% | 23.8% | 7.6% | 10.3% | 11.4% | 24.7% | 6.6% |
| Other Income | 0 | 3 | 0 | 3 | 5 | 2 | 2 | 3 | 7 | 2 | 0 | 3 |
| Interest | 2 | 2 | 1 | 2 | 0 | 1 | 2 | 2 | 1 | 1 | 1 | 1 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit before tax | 7 | 3 | 5 | 2 | 10 | 8 | 14 | 3 | 9 | 6 | 20 | 4 |
| Tax % | 24.9% | 38.2% | 30.6% | 93.3% | 16.7% | 32% | 26.2% | 34.5% | 14.5% | 22.9% | 26.4% | 48.8% |
| Net Profit | 5 | 2 | 4 | 0 | 9 | 6 | 10 | 2 | 8 | 4 | 15 | 2 |
| EPS in Rs | 1.35 | 0.83 | 1.03 | 0.38 | 2.46 | 1.7 | 2.97 | 0.87 | 2.34 | 1.27 | 4.15 | 0.83 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- 27%
- 5 Years
- 28%
- 3 Years
- 19%
- TTM
- 14%
- 10 Years
- 16%
- 5 Years
- 55%
- 3 Years
- 38%
- TTM
- 7%
- 10 Years
- 26%
- 5 Years
- 13%
- 3 Years
- 22%
- TTM
- —
- 10 Years
- 5%
- 5 Years
- 9%
- 3 Years
- 10%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Kilitch Drugs India Ltd | ₹ 220.00 | — | 25x | — | 11% | — |
| Sun Pharmaceutical Industries | ₹ 1,743.00 | ₹ 4,18,194 Cr. | 36.6x | 5.3x | 0% | 0% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 94.3x | 14.8x | 0% | 0% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 75.8x | 20x | 0% | 0% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 20.7x | 4.2x | 0% | 0% |
| Cipla | ₹ 1,337.00 | ₹ 1,08,011 Cr. | 26.6x | 3.2x | 0% | 0% |
Management
- Sunil Sureshji Jain
- Chief Financial Officer
- Pushpa Nyoupane
- Chief Compliance Officer, Company Secretary
- Mukund Prataprai Mehta
- Managing Director, Executive Director
- Mira Bhavin Mehta
- Managing Director
- Bhavin Mukund Mehta
- Wholetime Director
Prices are delayed and for information only. Nothing on this page is investment advice.